Pharmacologic approaches to the treatment of Huntington's disease

Charles S. Venuto(University of Rochester), Karl Kieburtz(Beth Israel Deaconess Medical Center), Qing Ma(H.B. Fuller (United States)), Andrew McGarry(Cooper Medical School of Rowan University)
Movement Disorders
October 13, 2011
10.1002/mds.23953
Cited by 84

Related Papers

Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss
|JAMA|2014|538
The Idiopathic Intracranial Hypertension Treatment Trial
|JAMA Neurology|2014|475
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
|JAMA Neurology|2014|239
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
|Neurology|2017|152
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
|Neurology|2016|137